Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTMX NASDAQ:EDIT NASDAQ:MRUS NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$3.30+0.6%$2.25$0.40▼$3.48$540.92M2.274.53 million shs3.79 million shsEDITEditas Medicine$3.92+0.8%$2.81$0.91▼$4.05$349.79M2.182.67 million shs3.33 million shsMRUSMerus$94.29+0.1%$69.49$33.19▼$94.56$7.12B1.263.68 million shs3.95 million shsSRPTSarepta Therapeutics$22.64+1.3%$18.39$10.41▼$138.81$2.18B0.516.24 million shs8.29 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics+0.61%+13.79%+55.66%+32.53%+186.96%EDITEditas Medicine+0.77%+20.99%+56.80%+51.64%+21.74%MRUSMerus+0.15%+36.87%+41.53%+75.13%+86.49%SRPTSarepta Therapeutics+1.30%+23.31%+19.47%+24.29%-81.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$3.30+0.6%$2.25$0.40▼$3.48$540.92M2.274.53 million shs3.79 million shsEDITEditas Medicine$3.92+0.8%$2.81$0.91▼$4.05$349.79M2.182.67 million shs3.33 million shsMRUSMerus$94.29+0.1%$69.49$33.19▼$94.56$7.12B1.263.68 million shs3.95 million shsSRPTSarepta Therapeutics$22.64+1.3%$18.39$10.41▼$138.81$2.18B0.516.24 million shs8.29 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics+0.61%+13.79%+55.66%+32.53%+186.96%EDITEditas Medicine+0.77%+20.99%+56.80%+51.64%+21.74%MRUSMerus+0.15%+36.87%+41.53%+75.13%+86.49%SRPTSarepta Therapeutics+1.30%+23.31%+19.47%+24.29%-81.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTMXCytomX Therapeutics 2.86Moderate Buy$5.4264.14% UpsideEDITEditas Medicine 2.14Hold$5.1030.10% UpsideMRUSMerus 2.18Hold$92.88-1.50% DownsideSRPTSarepta Therapeutics 2.07Hold$39.3273.67% UpsideCurrent Analyst Ratings BreakdownLatest SRPT, CTMX, EDIT, and MRUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/30/2025MRUSMerusUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$72.00 ➝ $97.009/30/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Hold9/30/2025MRUSMerusBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$112.00 ➝ $97.009/30/2025MRUSMerusBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$112.00 ➝ $97.009/30/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$109.00 ➝ $97.009/30/2025MRUSMerusLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$97.009/29/2025MRUSMerusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$135.00 ➝ $97.009/29/2025MRUSMerusCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$67.00 ➝ $97.009/29/2025MRUSMerusWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/29/2025MRUSMerusTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$88.00 ➝ $97.009/27/2025CTMXCytomX TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)(Data available from 10/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTMXCytomX Therapeutics$141.10M3.86$0.36 per share9.06($0.01) per share-330.00EDITEditas Medicine$38.90M9.06N/AN/A$1.63 per share2.40MRUSMerus$36.13M197.37N/AN/A$9.46 per share9.97SRPTSarepta Therapeutics$1.90B1.16$2.47 per share9.17$15.99 per share1.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTMXCytomX Therapeutics$31.87M$0.565.89N/AN/A34.04%158.70%36.04%11/6/2025 (Estimated)EDITEditas Medicine-$237.09M-$2.85N/AN/AN/A-608.88%-200.25%-68.57%11/3/2025 (Estimated)MRUSMerus-$215.33M-$5.50N/AN/AN/A-685.64%-50.28%-42.00%10/30/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$0.87N/A2.07N/A-2.34%-1.03%-0.37%11/5/2025 (Estimated)Latest SRPT, CTMX, EDIT, and MRUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025MRUSMerus-$1.20N/AN/AN/A$8.73 millionN/A8/12/2025Q2 2025EDITEditas Medicine-$0.41-$0.63-$0.22-$0.63$1.81 million$3.58 million8/6/2025Q2 2025SRPTSarepta Therapeutics$0.89$2.02+$1.13$1.89$530.66 million$611.09 million8/5/2025Q1 2025MRUSMerus-$1.17-$2.23-$1.06-$2.23$9.77 million$8.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTMXCytomX TherapeuticsN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTMXCytomX TherapeuticsN/A4.204.20EDITEditas MedicineN/A2.772.77MRUSMerusN/A8.398.39SRPTSarepta Therapeutics0.842.891.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTMXCytomX Therapeutics67.77%EDITEditas Medicine71.90%MRUSMerus96.14%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipCTMXCytomX Therapeutics6.60%EDITEditas Medicine2.10%MRUSMerus3.70%SRPTSarepta Therapeutics7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTMXCytomX Therapeutics170164.91 million154.03 millionOptionableEDITEditas Medicine23089.92 million88.03 millionOptionableMRUSMerus3775.63 million72.84 millionOptionableSRPTSarepta Therapeutics1,37297.71 million90.29 millionOptionableSRPT, CTMX, EDIT, and MRUS HeadlinesRecent News About These CompaniesSarepta (SRPT) on Soars 15.7% on 5th Day Ahead of Clinical Trial ResultsOctober 3 at 3:30 PM | insidermonkey.comSarepta: Q3 Earnings An Upcoming Catalyst, But Risks Undermine Any Contrarian PlayOctober 3 at 1:05 PM | seekingalpha.comSarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society CongressOctober 3 at 9:07 AM | businesswire.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from AnalystsOctober 3 at 2:15 AM | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Trading Up 10.4% - What's Next?October 2 at 12:46 PM | marketbeat.comGenerali Investments CEE investicni spolecnost a.s. Grows Position in Sarepta Therapeutics, Inc. $SRPTOctober 1 at 5:20 AM | marketbeat.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 30, 2025 | businesswire.comTempus Wealth Planning LLC Has $353,000 Holdings in Sarepta Therapeutics, Inc. $SRPTSeptember 29, 2025 | marketbeat.comCantor Fitzgerald Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)September 25, 2025 | theglobeandmail.comSarepta Therapeutics (SRPT) Receives a Hold from Evercore ISISeptember 25, 2025 | theglobeandmail.comKuehn Law Encourages Investors of Sarepta Therapeutics, Inc. to Contact Law FirmSeptember 24, 2025 | prnewswire.comSarepta Therapeutics (NASDAQ:SRPT) Raised to Outperform at BMO Capital MarketsSeptember 24, 2025 | americanbankingnews.comAssenagon Asset Management S.A. Purchases 155,358 Shares of Sarepta Therapeutics, Inc. $SRPTSeptember 23, 2025 | marketbeat.comBMO upgrades Sarepta on Elevidys uptake, pipeline prospectsSeptember 22, 2025 | au.investing.comBMO Capital Upgrades Sarepta Therapeutics (SRPT)September 22, 2025 | msn.comSarepta Therapeutics (NASDAQ:SRPT) Rating Increased to Outperform at BMO Capital MarketsSeptember 22, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 5.2% - Still a Buy?September 17, 2025 | marketbeat.comUBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Raises Stock Position in Sarepta Therapeutics, Inc. $SRPTSeptember 17, 2025 | marketbeat.comSarepta Therapeutics' (SRPT) Buy Rating Reiterated at GuggenheimSeptember 16, 2025 | marketbeat.comInspire Investing LLC Buys New Holdings in Sarepta Therapeutics, Inc. $SRPTSeptember 15, 2025 | marketbeat.comQ3 EPS Forecast for Sarepta Therapeutics Raised by AnalystSeptember 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSRPT, CTMX, EDIT, and MRUS Company DescriptionsCytomX Therapeutics NASDAQ:CTMX$3.30 +0.02 (+0.61%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$3.30 +0.01 (+0.15%) As of 10/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Editas Medicine NASDAQ:EDIT$3.92 +0.03 (+0.77%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$3.86 -0.06 (-1.53%) As of 10/3/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Merus NASDAQ:MRUS$94.29 +0.14 (+0.15%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$93.86 -0.44 (-0.46%) As of 10/3/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Sarepta Therapeutics NASDAQ:SRPT$22.64 +0.29 (+1.30%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$22.70 +0.05 (+0.24%) As of 10/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? How Berkshire's OxyChem Buy Cements Its Long-Term Strength NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Microsoft Stock Hits Stride in 2025—How Much More Can It Run? Datavault AI: The New AI Contender Backed by Big Funding Why GlobalFoundries Just Became a Geopolitical Power Play Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
